France, Ireland oppose Mysimba EU approval on safety/efficacy grounds
This article was originally published in Scrip
The EU CHMP's decision to recommend approval of Orexigen's weight loss combination product Mysimba (naltrexone/bupropion) has come under fire from the French and Irish regulatory agencies, whose representatives voted against the product's approval on safety and efficacy grounds at the committee's December meeting and have detailed their objections in a written statement.
You may also be interested in...
Russia seeks WHO endorsement of its Sputnik V vaccine, a UK BioIndustry Association taskforce identifies potential new antibody cocktails, and the European Centre for Disease Prevention and Control considers the best strategies for targeted vaccination programs.
New guidance from the UK covers the recognition of EU approvals, accelerated assessment, rolling reviews, and much else besides.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.